CN102382844B - Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method - Google Patents
Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method Download PDFInfo
- Publication number
- CN102382844B CN102382844B CN201110293170XA CN201110293170A CN102382844B CN 102382844 B CN102382844 B CN 102382844B CN 201110293170X A CN201110293170X A CN 201110293170XA CN 201110293170 A CN201110293170 A CN 201110293170A CN 102382844 B CN102382844 B CN 102382844B
- Authority
- CN
- China
- Prior art keywords
- rmp
- gene
- seq
- neisseria gonorrhoeae
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the field of medical microbiology, in particular to a neisseria gonorrhoeae immune repression mutant gene delta rmp and a mutant method. The neisseria gonorrhoeae immune repression mutant gene delta rmp has a nucleotide sequence shown as SEQ ID NO.10. The mutant gene is obtained by the following methods that: neisseria gonorrhoeae genomic deoxyribonucleic acid (DNA) is used as a template for carrying out polymerase chain reaction (PCR) amplification on the rmp gene, in addition, the rmp gene is connected into a T arrier pMD19, a connecting product pMD19rmp is used as a template for amplifying linear DNA fragments including the rmp gene downstream side wing region, pMD19 carrier framework and rmp gene upstream side wing region, the gene is connected with a kanamycin resistance gene Kanr subject to the same macrorestriction treatment, and the mutant gene delta rmp is obtained.
Description
Technical field
The present invention relates to the medical microbiology field, be specifically related to a kind of NEISSERIA GONORRHOEAE immunity repressor gene mutation method.
Background technology
NEISSERIA GONORRHOEAE (
Neisseriagonorrhoeae) natural host be human, cause the sexually transmitted disease (STD) gonorrhoea after the infection, can cause a series of pathologies, comprise local infection (like urethritis, epididymis inflammation, cervicitis, salpingitis etc.) and whole body disseminated infections.The pathology at position such as uterine tube, pelvic cavity can cause serious sequela such as Infertility or ectopic pregnancy.Gonorrhoea patient has also increased the morbidity chance of AIDS greatly.Incidence of Gonorrhea is high, global annual new cases about 6,200 ten thousand.Treatment has brought increasing difficulty to more and more serious NEISSERIA GONORRHOEAE resistance phenomenon to gonorrhoea.Therefore, developing effective vaccine is one of emphasis direction in the anti-system work of gonorrhoea.
It is difficult that the NEISSERIA GONORRHOEAE vaccine development is gone through, and the nineteen seventies human trial of whole-cell vaccines meets with failure, and the emphasis of research begins to turn to new generation vaccines such as subunit vaccine and gene vaccine.Pili be first by the NEISSERIA GONORRHOEAE subunit composition of purifying, although the pili behind the purifying can stimulate body to produce higher titer antibody, because some epi-position degrees of variation of pili surface are high, these antibody do not have significant immanoprotection action.Same owing to highly make a variation, another kind of important adhesion factor Opa albumen also is restricted in the gonorrhoea vaccine development.Porin is the I type outer membrane protein of continuous expression on the NEISSERIA GONORRHOEAE surface, has characteristics such as immunogenicity is strong, antigen is conservative relatively.The initial stage nineties was once carried out the animal immune experiment with the porin vaccine that covers most serotypes, and effect is not very good.Analyze its reason; Polluted a large amount of Rmp albumen in the porin vaccine that discovery is extracted from the NEISSERIA GONORRHOEAE cell, the latter is good immunogen, and its immunogenicity is higher than porin; Can stimulate body to produce complement fixation antibody; But these antibody not only do not have anti-microbial effect, can produce antagonistic action to the anti-microbial activity of porin antibody on the contrary, even can strengthen the infectivity of NEISSERIA GONORRHOEAE.Along with developing rapidly of genetic engineering technique, express the important directions that NEISSERIA GONORRHOEAE antigen becomes development gonorrhoea vaccine with genetic engineering technique.People successful expression multiple NEISSERIA GONORRHOEAE antigen; Like Porin, NspA, TbpA, TbpB, LOS etc.; Carry out purifying and renaturation with the protein correlation technique, cooperate certain adjuvant immunity mouse, finding all can inducing producing specificity protection antibody in the mouse body.
From the present Research analysis of present NEISSERIA GONORRHOEAE vaccine, it is very difficult preventing infection due to Neisseria gonorrhoeae fully with single a kind of antigenic NEISSERIA GONORRHOEAE vaccine.Although this vaccine can produce certain protection power,, if this inoculation just makes infection due to Neisseria gonorrhoeae transfer asymptomatic type to, the infected thereby do not seek medical advice, that can increase the propagation of NEISSERIA GONORRHOEAE on the contrary.Therefore, containing vaccine more even all NEISSERIA GONORRHOEAE protective antigens is optimal gonorrhoea vaccine candidate.
Summary of the invention
Contain immune repressor gene in the wild-type NEISSERIA GONORRHOEAE
Rmp, the product albumen Rmp of this gene can induce create antagonism harmful antibody of protection antibody of body.In order to solve the problems of the technologies described above, the invention provides a kind of sudden change
Rmp, and a kind of NEISSERIA GONORRHOEAE immunity repressor gene mutation method, thereby the effective ways of avoiding harmful antibody to produce have solved the bottleneck problem of developing the NEISSERIA GONORRHOEAE whole-cell vaccines.
The immune repressor gene Δ of sudden change of the present invention
Rmp,Its nucleotide sequence is shown in SEQ ID NO.10.
The immune repressor gene Δ of sudden change of the present invention
RmpObtain through following method: be to be template with the NEISSERIA GONORRHOEAE genomic dna, pcr amplification
RmpGene, and be connected among the T carrier pMD19, to connect product pMD19
RmpBe template, amplification comprises
RmpPterion, gene downstream side, pMD19 carrier framework and
RmpThe linear DNA fragment of upstream region of gene flanking region, the kalamycin resistance gene Kanr that cuts processing with same enzyme is connected, the mutator gene Δ that obtains
Rmp
Mutation method according to the invention comprises that step is following:
(1)
RmpThe clone of gene: with the NEISSERIA GONORRHOEAE genomic dna is template, is that primer goes out the NEISSERIA GONORRHOEAE of sequence shown in SEQ ID NO.3 through pcr amplification with the sequence of SEQ ID NO.1 and SEQ ID NO.2
RmpGene;
(2)
RmpThe amplification of upstream and downstream both sides flanking region: with what increase in above-mentioned (1)
RmpGene and pMD19-T carrier be connected product pMD19
RmpBe template, amplification comprises
RmpThe linear fragment of gene both sides flanking region; Amplification comprises
RmpForward and reverse primer sequence of gene both sides flanking region linear fragment is respectively shown in SEQ ID NO.4 and SEQ ID NO.5, and amplification obtains sequence comprising shown in SEQ ID NO.6
RmpThe linear fragment of gene both sides flanking region;
(3) be template with plasmid pET-28a (+), amplification Kanr gene order
Wherein primer sequence is shown in SEQ ID NO.7 and the SEQ ID NO.8, and the Kanr gene order that obtains through pcr amplification is shown in SEQ ID NO.9;
(4)
RmpThe insertion sudden change of gene
Carry what step (2) obtained
RmpGene both sides flanking region linear fragment is used
MluI with
XhoThe I double digestion is handled; The Kanr gene amplification product that step (3) obtains is with same double digestion digestion; The two connects with the T4 ligase enzyme after reclaiming purifying respectively; Connect product pMD19 Δ
RmpBe the NEISSERIA GONORRHOEAE immunity outside the middle carrier framework and check the mutator gene Δ
Rmp, its sequence is shown in SEQ ID NO.10.
With said mutation gene Δ
RmpBe cloned into suicide plasmid pGMB151, the electrotransformation suicide plasmid of will recombinating changes the NEISSERIA GONORRHOEAE cell over to.The SacB gene that suicide plasmid has can induce bacterium to slough plasmid and and wild-type
RmpHomologous recombination takes place, thereby obtains
Rmp-mutant strain.
Adopting single antigen or 2 kinds of antigen group cooperations in the NEISSERIA GONORRHOEAE vaccine development at present is vaccine; The antigen limited amount that contains; And NEISSERIA GONORRHOEAE is a kind of thousands of kinds of proteic bacteriums that contain, and the vaccine that limited quantity antigen is made is difficult to stimulate body to produce enough immunoprotections.Method provided by the invention; Because of mutant strain can not be expressed NEISSERIA GONORRHOEAE immunity repressor gene; Having removed NEISSERIA GONORRHOEAE induces body to produce the possibility of harmful antibody; Thereby can prepare the whole-cell vaccines that only stimulate body to produce favourable antibody, for the development of gonorrhoea new generation vaccine brings new breakthrough.
Description of drawings
Fig. 1 is
RmpThe agarose gel electrophoresis analysis of gene amplification product.
Fig. 2 comprises
RmpPterion, gene downstream side, pMD19 carrier framework and
RmpUpstream region of gene flanking region linear DNA fragment agarose gel electrophoresis is analyzed.
Fig. 3 comprises
RmpPterion, gene downstream side, pMD19 carrier framework and
RmpThe structural representation of upstream region of gene flanking region linear DNA fragment.
Fig. 4. be the analysis of Kanr gene amplification product agarose gel electrophoresis.
Fig. 5 is a NEISSERIA GONORRHOEAE
RmpThe PCR screening of-mutant strain, wherein 1 negative contrast; 2-3 does
RmpGot into cell but replaced normal as yet
RmpThe bacterial strain of gene can amplify simultaneously
RmpWith
RmpGene; 4 is wild strain, can only amplify
RmpGene; 5 is mutant strain, can only amplify
RmpGene.
Fig. 6 is a NEISSERIA GONORRHOEAE
RmpThe Western blotting of-mutant strain identifies that wherein 1 is wild strain, still expresses Rmp albumen; 2 is mutant strain, does not express Rmp albumen.
Embodiment
With PCR with in the NEISSERIA GONORRHOEAE genome
RmpAmplification is come out, and one section of the centre of this gene with the Kanr resistant gene replacement from pET28a, is obtained being inserted into the mutator gene of inactivation
Rmp, the latter is connected in the suicide vector, carries
RmpThe reorganization suicide vector be placed in the intestinal bacteria, intestinal bacteria and NEISSERIA GONORRHOEAE hatch altogether, and suicide vector is transformed in the wild-type NEISSERIA GONORRHOEAE bacterial strain, screen then and identify after the homologous recombination wild
RmpQuilt
RmpThe mutant strain of replacement.
Embodiment one:
(1)
RmpThe amplification of the clone of gene and both sides flanking region thereof
1,
RmpThe clone of gene
With the NEISSERIA GONORRHOEAE genomic dna is template,
With F:5 ' CG
GGATCCATGACCAAACAGCTGAAATTAAG 3 ' (
Bam HI) (SEQ ID NO.1) and R:5 ' CCC
GGATCCTTAGTGTTGGTGATGATTGCGT 3 ' (
BamH I) sequence of (SEQ ID NO.2) is that primer goes out in the NEISSERIA GONORRHOEAE genome through pcr amplification
RmpGene (Fig. 1), amplified production is through order-checking, and sequence is shown in SEQ ID NO.3:
Among the SEQ ID NO.3,267-466 will be partly for will (being made by the replacement of Kanr resistant gene
RmpThe insertion inactivation) part, two ends line capitalization partly does
Bam HThe I recognition site.
2.
RmpThe amplification of upstream and downstream both sides flanking region
With above-mentioned
RmpGene amplification product is connected with T carrier pMD-19T, and is that template amplification comprises to connect product
RmpA linear fragment of gene both sides flanking region, the agarose gel electrophoresis analysis 2 of this linear fragment, this linear fragment structural representation such as Fig. 3.
Amplification comprises
RmpForward and reverse primer of gene both sides flanking region linear fragment is respectively:
F:5’TGC
CTCGAGTAGTGGCAAACAACCTGGTC?3?’?(
Xho?I)?(SEQ?ID?NO.4)
R:5 ' GTC
ACGCGT TTATCTACTCAACATATTGAGGAGCCTGC 3 ' (
MluI) (SEQ ID NO.5), wherein
TTATCTACTCABe terminator sequence.
The amplification obtain comprise the pMD-19 carrier with
Rmp(front end does the sequence of the linear fragment of gene both sides flanking region shown in SEQ ID NO.6
XhoThe I recognition site; 258-2968bp partly is the pMD-19 skeleton; End does
MluThe I recognition site; Wherein 7-257bp partly does
RmpGene
DownstreamFlanking region, 2969-3228bp partly do
RmpGene
The upper reachesFlanking region).
(2) be template amplification Kanr gene order with plasmid pET-28a (+)
Primer sequence is:
F:5’TCG
ACGCGTGCTCAGTGGAACGAAAACTC 3?’?(?
Mlu?I)(SEQ?ID?NO.7)
R:5’GCG
CTCGAG CTTAGAAAAACTCATCGAGCAT 3?’?(
Xho?I)(SEQ?ID?NO.8)
With after pMD-19T is connected, make this carrier obtain kalamycin resistance through Kanr gene amplification product (Fig. 4) that pcr amplification obtains, show that the dna fragmentation of amplification has activity; Product is through order-checking, and (two ends are respectively sequence shown in SEQ ID NO.9
MluI with
XhoThe I recognition site).
(3)
RmpThe insertion sudden change of gene
With SEQ ID NO.6 (
RmpPterion, gene downstream side, pMD19 carrier framework and
RmpThe linear DNA fragment of upstream region of gene flanking region) and the dna fragmentation of SEQ ID NO.9 (Kanr gene) use respectively
MluI with
XhoThe I double digestion, and reclaim purifying; The two connects with the T4 ligase enzyme, promptly contains in the annular DNA fragment of acquisition
RmpThe gene middle portion is by the mutator gene Δ of activated Kanr gene replacement
RmpWith the pMP-19 carrier framework, called after pMD19 Δ
Rmp, Δ wherein
RmpSequence is shown in SEQ ID NO.10.
Embodiment two:
To comprise the mutator gene Δ
RmpRecombinant vectors pMD19 Δ
RmpWith suicide vector pGMB151 (X. X Huang, L. V. Phung, S. Dejsirilert, et al., " Cloning and characterization of the gene encoding the z66 antigen of
Salmonella entericaSerovar Typhi, "
FEMS Microbiology Letters, 2006,234 (2): 239 – 246) use respectively
Bam HThe I enzymic digestion, the latter two connect with the T4 ligase enzyme to reclaim purifying, and the connection product of acquisition transforms through electricity and imports host e. coli SPY372 λ pir, and the intestinal bacteria and the wild-type NEISSERIA GONORRHOEAE of carrying the reorganization suicide vector hatch altogether.The dead cracking of intestinal bacteria in the process that goes down to posterity, the reorganization suicide vector of release gets into NEISSERIA GONORRHOEAE, and with the NEISSERIA GONORRHOEAE wild-type
RmpHomologous recombination takes place, and makes wild
RmpSuddenlyd change
RmpReplace, lose the suicide vector framework simultaneously.Show as mutant strain and have the kana resistance, but lost amp and the sm resistance on the carrier.Isolating NEISSERIA GONORRHOEAE bacterium colony after extraction is gone down to posterity extracts genomic dna and makes template, uses
RmpPrimer carries out PCR, only filters out to amplify
RmpBacterial strain, be
Rmp-mutant strain, (Fig. 5); Show Rmp protein expression disappearance (Fig. 6) in this mutant strain with Western blotting evaluation.
SEQUENCE?LISTING
< 110>Yangzhou University
< 120>mutator gene Δ rmp and mutation method are checked in a kind of NEISSERIA GONORRHOEAE immunity
<130>
<160> 10
<170> PatentIn?version?3.3
<210> 1
<211> 31
<212> DNA
< 213>artificial sequence
<400> 1
cgggatccat?gaccaaacag?ctgaaattaa?g 31
<210> 2
<211> 31
<212> DNA
< 213>artificial sequence
<400> 2
cccggatcct?tagtgttggt?gatgattgcg?t 31
<210> 3
<211> 723
<212> DNA
< 213>NEISSERIA GONORRHOEAE
<400> 3
ggatccatga?ccaaacagct?gaaattaagc?gcattattcg?ttgcattgct?cgcttccggc 60
actgctgttg?cgggcgaggc?gtccgttcag?ggttacaccg?taagcggcca?gtcgaacgaa 120
atcgtacgca?acaactatgg?agaatgctgg?aaaaacgcct?actttgataa?agcaagccaa 180
ggtcgcgtag?aatgcggcga?tgcggttgcc?gtccccgagc?ccgaacccgc?gcctgtcgcc 240
gttgtggagc?aggctcctca?atatgttgat?gaaaccattt?ccctgtctgc?caaaaccctg 300
ttcggtttcg?ataaggattc?attgcgcgcc?gaagctcaag?acaacctgaa?agtattggcg 360
caacgcctga?gtcgaaccaa?tgtccaatct?gtccgcgtcg?aaggccatac?cgactttatg 420
ggttctgaaa?aatacaatca?ggctctgtcc?gaacgccgcg?catacgtagt?ggcaaacaac 480
ctggtcagca?acggcgtacc?tgcttctaga?atttctgctg?tcggcttggg?cgaatctcaa 540
gcgcaaatga?ctcaagtttg?tcaagccgaa?gttgccaaac?tgggtgcgaa?agcctctaaa 600
gccaaaaaac?gtgaggctct?gattgcatgt?atcgaacctg?accgccgcgt?agatgtgaaa 660
atccgcagca?tcgtaacccg?tcaggttgtg?ccggcacgca?atcatcacca?acactaagga 720
tcc 723
<210> 4
<211> 29
<212> DNA
< 213>artificial sequence
<400> 4
tgcctcgagt?agtggcaaac?aacctggtc 29
<210> 5
<211> 38
<212> DNA
< 213>artificial sequence
<400> 5
gtcacgcgtt?tatctactca?acatattgag?gagcctgc 38
<210> 6
<211> 3245
<212> DNA
< 213>artificial sequence
<400> 6
ctcgagtagt?ggcaaacaac?ctggtcagca?acggcgtacc?tgcttctaga?atttctgctg 60
tcggcttggg?cgaatctcaa?gcgcaaatga?ctcaagtttg?tcaagccgaa?gttgccaaac 120
tgggtgcgaa?agcctctaaa?gccaaaaaac?gtgaggctct?gattgcatgt?atcgaacctg 180
accgccgcgt?agatgtgaaa?atccgcagca?tcgtaacccg?tcaggttgtg?ccggcacgca 240
atcatcacca?acactaagga?tccgggaatc?tctagaggat?ccccgggtac?cgagctcgaa 300
ttcactggcc?gtcgttttac?aacgtcgtga?ctgggaaaac?cctggcgtta?cccaacttaa 360
tcgccttgca?gcacatcccc?ctttcgccag?ctggcgtaat?agcgaagagg?cccgcaccga 420
tcgcccttcc?caacagttgc?gcagcctgaa?tggcgaatgg?cgcctgatgc?ggtattttct 480
ccttacgcat?ctgtgcggta?tttcacaccg?catatggtgc?actctcagta?caatctgctc 540
tgatgccgca?tagttaagcc?agccccgaca?cccgccaaca?cccgctgacg?cgccctgacg 600
ggcttgtctg?ctcccggcat?ccgcttacag?acaagctgtg?accgtctccg?ggagctgcat 660
gtgtcagagg?ttttcaccgt?catcaccgaa?acgcgcgaga?cgaaagggcc?tcgtgatacg 720
cctattttta?taggttaatg?tcatgataat?aatggtttct?tagacgtcag?gtggcacttt 780
tcggggaaat?gtgcgcggaa?cccctatttg?tttatttttc?taaatacatt?caaatatgta 840
tccgctcatg?agacaataac?cctgataaat?gcttcaataa?tattgaaaaa?ggaagagtat 900
gagtattcaa?catttccgtg?tcgcccttat?tccctttttt?gcggcatttt?gccttcctgt 960
ttttgctcac?ccagaaacgc?tggtgaaagt?aaaagatgct?gaagatcagt?tgggtgcacg 1020
agtgggttac?atcgaactgg?atctcaacag?cggtaagatc?cttgagagtt?ttcgccccga 1080
agaacgtttt?ccaatgatga?gcacttttaa?agttctgcta?tgtggcgcgg?tattatcccg 1140
tattgacgcc?gggcaagagc?aactcggtcg?ccgcatacac?tattctcaga?atgacttggt 1200
tgagtactca?ccagtcacag?aaaagcatct?tacggatggc?atgacagtaa?gagaattatg 1260
cagtgctgcc?ataaccatga?gtgataacac?tgcggccaac?ttacttctga?caacgatcgg 1320
aggaccgaag?gagctaaccg?cttttttgca?caacatgggg?gatcatgtaa?ctcgccttga 1380
tcgttgggaa?ccggagctga?atgaagccat?accaaacgac?gagcgtgaca?ccacgatgcc 1440
tgtagcaatg?gcaacaacgt?tgcgcaaact?attaactggc?gaactactta?ctctagcttc 1500
ccggcaacaa?ttaatagact?ggatggaggc?ggataaagtt?gcaggaccac?ttctgcgctc 1560
ggcccttccg?gctggctggt?ttattgctga?taaatctgga?gccggtgagc?gtgggtctcg 1620
cggtatcatt?gcagcactgg?ggccagatgg?taagccctcc?cgtatcgtag?ttatctacac 1680
gacggggagt?caggcaacta?tggatgaacg?aaatagacag?atcgctgaga?taggtgcctc 1740
actgattaag?cattggtaac?tgtcagacca?agtttactca?tatatacttt?agattgattt 1800
aaaacttcat?ttttaattta?aaaggatcta?ggtgaagatc?ctttttgata?atctcatgac 1860
caaaatccct?taacgtgagt?tttcgttcca?ctgagcgtca?gaccccgtag?aaaagatcaa 1920
aggatcttct?tgagatcctt?tttttctgcg?cgtaatctgc?tgcttgcaaa?caaaaaaacc 1980
accgctacca?gcggtggttt?gtttgccgga?tcaagagcta?ccaactcttt?ttccgaaggt 2040
aactggcttc?agcagagcgc?agataccaaa?tactgttctt?ctagtgtagc?cgtagttagg 2100
ccaccacttc?aagaactctg?tagcaccgcc?tacatacctc?gctctgctaa?tcctgttacc 2160
agtggctgct?gccagtggcg?ataagtcgtg?tcttaccggg?ttggactcaa?gacgatagtt 2220
accggataag?gcgcagcggt?cgggctgaac?ggggggttcg?tgcacacagc?ccagcttgga 2280
gcgaacgacc?tacaccgaac?tgagatacct?acagcgtgag?ctatgagaaa?gcgccacgct 2340
tcccgaaggg?agaaaggcgg?acaggtatcc?ggtaagcggc?agggtcggaa?caggagagcg 2400
cacgagggag?cttccagggg?gaaacgcctg?gtatctttat?agtcctgtcg?ggtttcgcca 2460
cctctgactt?gagcgtcgat?ttttgtgatg?ctcgtcaggg?gggcggagcc?tatggaaaaa 2520
cgccagcaac?gcggcctttt?tacggttcct?ggccttttgc?tggccttttg?ctcacatgtt 2580
ctttcctgcg?ttatcccctg?attctgtgga?taaccgtatt?accgcctttg?agtgagctga 2640
taccgctcgc?cgcagccgaa?cgaccgagcg?cagcgagtca?gtgagcgagg?aagcggaaga 2700
gcgcccaata?cgcaaaccgc?ctctccccgc?gcgttggccg?attcattaat?gcagctggca 2760
cgacaggttt?cccgactgga?aagcgggcag?tgagcgcaac?gcaattaatg?tgagttagct 2820
cactcattag?gcaccccagg?ctttacactt?tatgcttccg?gctcgtatgt?tgtgtggaat 2880
tgtgagcgga?taacaatttc?acacaggaaa?cagctatgac?catgattacg?ccaagcttgc 2940
atgcctgcag?gtcgacgatt?cgggatccat?gaccaaacag?ctgaaattaa?gcgcattatt 3000
cgttgcattg?ctcgcttccg?gcactgctgt?tgcgggcgag?gcgtccgttc?agggttacac 3060
cgtaagcggc?cagtcgaacg?aaatcgtacg?caacaactat?ggagaatgct?ggaaaaacgc 3120
ctactttgat?aaagcaagcc?aaggtcgcgt?agaatgcggc?gatgcggttg?ccgtccccga 3180
gcccgaaccc?gcgcctgtcg?ccgttgtgga?gcaggctcct?caatatgttg?agtagataaa 3240
cgcgt 3245
<210> 7
<211> 29
<212> DNA
< 213>artificial sequence
<400> 7
tcgacgcgtg?ctcagtggaa?cgaaaactc 29
<210> 8
<211> 31
<212> DNA
< 213>artificial sequence
<400> 8
gcgctcgagc?ttagaaaaac?tcatcgagca?t 31
<210> 9
<211> 917
<212> DNA
< 213>artificial sequence
<400> 9
acgcgtgctc?agtggaacga?aaactcacgt?taagggattt?tggtcatgaa?caataaaact 60
gtctgcttac?ataaacagta?atacaagggg?tgttatgagc?catattcaac?gggaaacgtc 120
ttgctctagg?ccgcgattaa?attccaacat?ggatgctgat?ttatatgggt?ataaatgggc 180
tcgcgataat?gtcgggcaat?caggtgcgac?aatctatcga?ttgtatggga?agcccgatgc 240
gccagagttg?tttctgaaac?atggcaaagg?tagcgttgcc?aatgatgtta?cagatgagat 300
ggtcagacta?aactggctga?cggaatttat?gcctcttccg?accatcaagc?attttatccg 360
tactcctgat?gatgcatggt?tactcaccac?tgcgatcccc?gggaaaacag?cattccaggt 420
attagaagaa?tatcctgatt?caggtgaaaa?tattgttgat?gcgctggcag?tgttcctgcg 480
ccggttgcat?tcgattcctg?tttgtaattg?tccttttaac?agcgatcgcg?tatttcgtct 540
cgctcaggcg?caatcacgaa?tgaataacgg?tttggttgat?gcgagtgatt?ttgatgacga 600
gcgtaatggc?tggcctgttg?aacaagtctg?gaaagaaatg?cataaacttt?tgccattctc 660
accggattca?gtcgtcactc?atggtgattt?ctcacttgat?aaccttattt?ttgacgaggg 720
gaaattaata?ggttgtattg?atgttggacg?agtcggaatc?gcagaccgat?accaggatct 780
tgccatccta?tggaactgcc?tcggtgagtt?ttctccttca?ttacagaaac?ggctttttca 840
aaaatatggt?attgataatc?ctgatatgaa?taaattgcag?tttcatttga?tgctcgatga 900
gtttttctaa?gctcgag 917
<210> 10
<211> 1451
<212> DNA
< 213>artificial sequence
<400> 10
ggatccatga?ccaaacagct?gaaattaagc?gcattattcg?ttgcattgct?cgcttccggc 60
actgctgttg?cgggcgaggc?gtccgttcag?ggttacaccg?taagcggcca?gtcgaacgaa 120
atcgtacgca?acaactatgg?agaatgctgg?aaaaacgcct?actttgataa?agcaagccaa 180
ggtcgcgtag?aatgcggcga?tgcggttgcc?gtccccgagc?ccgaacccgc?gcctgtcgcc 240
gttgtggagc?aggctcctca?atatgttgag?tagataaacg?cgtgctcagt?ggaacgaaaa 300
ctcacgttaa?gggattttgg?tcatgaacaa?taaaactgtc?tgcttacata?aacagtaata 360
caaggggtgt?tatgagccat?attcaacggg?aaacgtcttg?ctctaggccg?cgattaaatt 420
ccaacatgga?tgctgattta?tatgggtata?aatgggctcg?cgataatgtc?gggcaatcag 480
gtgcgacaat?ctatcgattg?tatgggaagc?ccgatgcgcc?agagttgttt?ctgaaacatg 540
gcaaaggtag?cgttgccaat?gatgttacag?atgagatggt?cagactaaac?tggctgacgg 600
aatttatgcc?tcttccgacc?atcaagcatt?ttatccgtac?tcctgatgat?gcatggttac 660
tcaccactgc?gatccccggg?aaaacagcat?tccaggtatt?agaagaatat?cctgattcag 720
gtgaaaatat?tgttgatgcg?ctggcagtgt?tcctgcgccg?gttgcattcg?attcctgttt 780
gtaattgtcc?ttttaacagc?gatcgcgtat?ttcgtctcgc?tcaggcgcaa?tcacgaatga 840
ataacggttt?ggttgatgcg?agtgattttg?atgacgagcg?taatggctgg?cctgttgaac 900
aagtctggaa?agaaatgcat?aaacttttgc?cattctcacc?ggattcagtc?gtcactcatg 960
gtgatttctc?acttgataac?cttatttttg?acgaggggaa?attaataggt?tgtattgatg 1020
ttggacgagt?cggaatcgca?gaccgatacc?aggatcttgc?catcctatgg?aactgcctcg 1080
gtgagttttc?tccttcatta?cagaaacggc?tttttcaaaa?atatggtatt?gataatcctg 1140
atatgaataa?attgcagttt?catttgatgc?tcatgaggtt?tttctaagct?cgagtagtgg 1200
caaacaacct?ggtcagcaac?ggcgtacctg?cttctagaat?ttctgctgtc?ggcttgggcg 1260
aatctcaagc?gcaaatgact?caagtttgtc?aagccgaagt?tgccaaactg?ggtgcgaaag 1320
cctctaaagc?caaaaaacgt?gaggctctga?ttgcatgtat?cgaacctgac?cgccgcgtag 1380
atgtgaaaat?ccgcagcatc?gtaacccgtc?aggttgtgcc?ggcacgcaat?catcaccaac 1440
actaaggatc?c 1451
Claims (2)
- A NEISSERIA GONORRHOEAE ( Neisseriagonorrhoeae) immunity checks the mutator gene Δ Rmp,Its nucleotide sequence is shown in SEQ ID NO.10.
- 2. the mutator gene Δ is checked in a NEISSERIA GONORRHOEAE immunity RmpMutation method, it is characterized in that, be to be template with the NEISSERIA GONORRHOEAE genomic dna, pcr amplification RmpGene, and be connected among the T carrier pMD19, to connect product pMD19 RmpBe template, amplification comprises RmpPterion, gene downstream side, pMD19 carrier framework and RmpThe linear DNA fragment of upstream region of gene flanking region is with identical MluI with XhoThe kalamycin resistance gene Kanr that the I double digestion is handled connects, the mutator gene Δ that obtains RmpConcrete steps are following:(1) RmpThe clone of gene: with the NEISSERIA GONORRHOEAE genomic dna is template, is that primer goes out the NEISSERIA GONORRHOEAE of sequence shown in SEQ ID NO.3 through pcr amplification with the sequence of SEQ ID NO.1 and SEQ ID NO.2 RmpGene;(2) RmpThe amplification of upstream and downstream both sides flanking region: with what increase in above-mentioned (1) RmpGene and pMD19-T carrier be connected product pMD19 RmpBe template, amplification comprises RmpThe linear fragment of gene both sides flanking region; Amplification comprises RmpForward and reverse primer sequence of gene both sides flanking region linear fragment is respectively shown in SEQ ID NO.4 and SEQ ID NO.5, and amplification obtains sequence comprising shown in SEQ ID NO.6 RmpThe linear fragment of gene both sides flanking region;(3) be template with plasmid pET-28a (+), amplification Kanr gene orderWherein primer sequence is shown in SEQ ID NO.7 and the SEQ ID NO.8, and the Kanr gene order that obtains through pcr amplification is shown in SEQ ID NO.9;(4) RmpThe insertion sudden change of geneCarry what step (2) obtained RmpGene both sides flanking region linear fragment is used MluI with XhoThe I double digestion is handled; The Kanr gene amplification product that step (3) obtains is with same double digestion digestion; The two connects with the T4 ligase enzyme after reclaiming purifying respectively; Connect product pMD19 Δ RmpBe the NEISSERIA GONORRHOEAE immunity outside the middle carrier framework and check the mutator gene Δ Rmp, its sequence is shown in SEQ ID NO.10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110293170XA CN102382844B (en) | 2011-10-07 | 2011-10-07 | Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110293170XA CN102382844B (en) | 2011-10-07 | 2011-10-07 | Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102382844A CN102382844A (en) | 2012-03-21 |
CN102382844B true CN102382844B (en) | 2012-11-21 |
Family
ID=45822674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110293170XA Expired - Fee Related CN102382844B (en) | 2011-10-07 | 2011-10-07 | Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102382844B (en) |
-
2011
- 2011-10-07 CN CN201110293170XA patent/CN102382844B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102382844A (en) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111705006B (en) | Oral recombinant yeast for expressing novel coronavirus S protein and preparation and application thereof | |
US5159062A (en) | Signal peptide for the secretion of peptides in escherichia coli | |
JP2005336206A (en) | Recombinant racoon poxvirus and its use as effective vaccine against feline infectious peritonitis virus disease | |
CN108823226A (en) | A kind of Chinese soybean mosaic virus infectious clone carrier and its construction method and application | |
CN102719471B (en) | Integrative plasmid pOPHI and resistance screening marker-free self-luminescent mycobacterium | |
CN114085918B (en) | RPA-CRISPR/Cas12a-FQ system and application thereof in environmental water body biological detection | |
KR101495276B1 (en) | Light Inducible Promoter and Gene Expression System Comprising The Same | |
CN112501139B (en) | Recombinant Newcastle disease virus strain and preparation method and application thereof | |
CN113736676A (en) | Preparation and application of oral recombinant saccharomyces cerevisiae for expressing porcine epidemic diarrhea virus S protein | |
CN110108884A (en) | A kind of ELISA detection method for canine distemper virus and antibody | |
CN104328136B (en) | The preparation of Newcastle disease poison strain rClone30 fliC and its application in Newcastle disease prevention | |
CN113073102B (en) | Application of autophagy gene ATG9 in rice breeding and/or rice grain type mechanism research | |
CN104357409B (en) | Express chicken IL2 recombinant Newcastle disease virus and its application in vaccine | |
CN102382844B (en) | Neisseria gonorrhoeae immune repression mutant gene delta rmp and mutant method | |
KR20140094757A (en) | A cassette comprising promoter sequences of a target gene and a method for gene manipulation using the same | |
CN101220372B (en) | Recombined bifidobacteria -hRV/VP7 expression vector and oral vaccine thereof | |
CN111748034B (en) | Preparation method of mycoplasma synoviae monoclonal antibody | |
CN108118047A (en) | A kind of preparation method of bifunctional enzyme and its application in trehalose production | |
CN113817621B (en) | Recombinant saccharomyces cerevisiae strain capable of simultaneously expressing IFNa14 protein and human hepatitis B virus S protein as well as preparation method and application thereof | |
CN113862207B (en) | Modified strain, application thereof in preparation of intestinal motility promoting preparation and product | |
CN109321601B (en) | AQP5 recombinant overexpression vector and construction method and application thereof | |
CN114085863B (en) | Double ARS vector capable of free expression in candida glycerinogenes and application thereof | |
CN113234691B (en) | Biological fluorescent probe for dynamically monitoring cholecystokinin and application thereof | |
CN114480407B (en) | Clec126 gene in caenorhabditis elegans genome and application thereof | |
CN112322658A (en) | Recombinant goat pox virus co-expressing peste des petits ruminants virus H and F proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20151007 |
|
EXPY | Termination of patent right or utility model |